Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235961 · ClinicalTrials.gov registry record · Phase 1
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 163
- Enrollment target
NCT02235961 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 163 participants.
The verdict
NCT02235961, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 163 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone and in combination with liraglutide in overweight to obese but otherwise healthy male subjects.
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG NNC9204-0530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2016-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235961
The ClinicalTrials.gov registry entry for NCT02235961 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02235961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02235961 about?
NCT02235961 is a clinical study titled "Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects". This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone and in combination with liraglutide in overweight to obese but otherwise...
What is the current status of trial NCT02235961?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 163 participants. The study started on 2014-09-04. Estimated completion is 2016-07-06.
What interventions are being tested in trial NCT02235961?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), NNC9204-0530 (DRUG).
Who is sponsoring clinical trial NCT02235961?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.